TrovaGene (TROV) Stock: Gaining Big On Clinical Data Presentation

Trovagene TROV Stock News

TrovaGene Inc (NASDAQ: TROV) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced updated results following a presentation at AACR. As you could imagine, the positive data excited investors who are pushing the stock on a run for the top. Today, we’ll talk about: The … Read more

Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib

Trovagene TROV Stock News

We all know what cancer is. The debilitating, often life-threatening condition can be incredibly difficult to treat. As a result, new therapies are being developed in an effort to bring improved treatment options to patients, especially for some of the toughest-to-treat cancers. That’s where Trovagene (Nasdaq: TROV) comes in with their drug candidate, Onvansertib. Trovagene caught … Read more

Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib

We all know what cancer is. The debilitating, often life-threatening condition can be incredibly difficult to treat. As a result, new therapies are being developed in an effort to bring improved treatment options to patients, especially for some of the toughest-to-treat cancers. That’s where Trovagene (Nasdaq: TROV) comes in with their drug candidate, Onvansertib. Trovagene … Read more

TrovaGene (TROV) Stock: Climbing On Coming Clinical Update

TrovaGene Inc (NASDAQ: TROV) is having a great start to the trading session this morning, and for good reason. The company said that it will be providing a clinical update relatively soon, exciting investors and sending the stock screaming for the top. Today, we’ll talk about: The clinical update; what we’re seeing from TROV stock … Read more

TrovaGene (TROV) Stock: Tumbling After Pricing Offering

TrovaGene Inc (NASDAQ: TROV) is having an overwhelmingly strong start to the trading session this morning after the company announced the pricing of a public offering. Unfortunately for those already involved in the stock, the dilutive offering came at a massively discounted price. Of course, the news disappointed investors who have sent the stock spiraling out … Read more